Rodgers.Manual de hematología clínica_5ed

383

CAPÍTULO 22 ■ TROMBOEMBOLIA VENOSA

18. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med . 2006;355:2797. 19. Rose SC, Zwiebel WJ, Nelson BD, et al. Symptomatic lower extremity deep venous thrombosis: accuracy, limitations, and role of color duplex flow imaging in diagnosis. Radiology . 1990;175(3):639-644. doi:10.1148/radiology.175.3.2188293. Erratum in: Radiology . 1990;176(3):879. 20. Segal J, Eng J, Tamariz L, et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Clin ical practice guideline. American College of Physicians. Ann Fam Med . 2007;5:63‐73. 21. Kalva SP, Jagannathan JP, Hahn PF, Wicky ST. Venous thromboembolism: indirect CT venography during CT pulmonary angi ography—should the pelvis be imaged? Radiology . 2008;246(2):605‐611. doi:10.1148/radiol.2462070319 22. Stein PD, Fowler SE, Goodman LR, et al.; PIOPED II Investigators. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med . 2006;354(22):2317‐2327. doi:10.1056/NEJMoa052367 23. PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investi gation of pulmonary embolism diagnosis (PIOPED). JAMA . 1990;263(20):2753‐2759. doi:10.1001/jama.1990.03440200057023 24. Wittram C, Waltman AC, Shepard JA, Halpern E, Goodman LR. Discordance between CT and angiography in the PIOPED II study. Radiology . 2007;244(3):883‐889. doi:10.1148/radiol.2443061693 25. Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein throm bosis. Hepatology . 2000;31:345‐348. 26. Denninger M-H, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple con current factors. Hepatology . 2000;31:587‐591. 27. Jansen HLA, Meinardi JR, Vleggar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coag ulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood . 2000;96:2364‐2368. 28. Coutinho JM, Ferro JM, Canhão P, et al. Cerebral venous and sinus thrombosis in women. Stroke . 2009;40(7):2356‐2361. doi:10.1161/STROKEAHA.108.543884 29. Ferro JM, Coutinho JM, Dentali F, et al.; RE-SPECT CVT Study Group. Safety and efficacy of dabigatran etexilate vs dose-ad justed warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol . 2019;76(12):1457‐1465. doi:10.1001/jamaneurol.2019.2764 30. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood . 2005;106(8):2710‐2715. doi:10.1182/blood-2005-04-1546 31. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest . 2007;131(6):1644‐1649. doi:10.1378/chest.06-2109 32. Warkentin T. How I diagnose and manage HIT. ASH Education Book. Hematology Am Soc Hematol Educ Program . 2011;2011:143‐149. 33. Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost . 2017;15(11):2099‐2114. doi:10.1111/jth.13813 34. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol . 2003;121:535‐555. 35. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv . 2018;2(22):3360‐3392. doi:10.1182/bloodadvances. 2018024489 36. Warkentin TE, Sheppard JI, Linkins LA, Arnold DM, Nazy I. Performance characteristics of an automated latex immuno turbidimetric assay [HemosIL® HIT-Ab (PF4-H) ] for the diagnosis of immune heparin-induced thrombocytopenia. Thromb Res . 2017;153:108‐117. doi:10.1016/j.thromres.2017.03.010 37. Papadopoulos S, Flynn JD, Lewis DA. Fondaparinux as a treatment option for heparin-induced thrombocytopenia. Pharmaco therapy . 2007;27:921‐926. 38. Pendleton R, Wheeler MM, Rodgers GM. Argatroban dosing of patients with heparin-induced thrombocytopenia and an ele vated aPTT due to antiphospholipid antibody syndrome. Ann Pharmacother . 2006;40:972‐976. 39. Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res . 2006;118:397‐407. 40. Mahmoodi BK, ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation . 2008;117:224‐230. 41. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med . 1999;340:448‐454. 42. Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet . 2010;376(9751):1498‐1509. 43. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med . 2013;368(11):1033‐1044. doi:10.1056/NEJMra1112830 44. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost . 2006;4(2):295‐306. doi:10.1111/j.1538-7836.2006.01753.x 45. Pengo V, Banzato A, Bison E, Zoppellaro G, Padayattil Jose S, Denas G. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus . 2016;25(3):301‐306. doi:10.1177/0961203315611495

Copyright © 2025 Wolters Kluwer, Inc. Unauthorized reproduction of the content is prohibited.